Participated · Equity · Jun 2026

Neuronostics develops BioEP, a clinically validated digital biomarker platform that analyses standard EEG recordings using eight predefined computational biomarkers and produces a report in under five minutes. The platform is UKCA-marked and ISO-13485 certified and has been validated across 15 NHS sites with over 1,000 recordings. NHS service evaluations are underway at multiple Trusts, including The Royal Wolverhampton NHS Trust and University Hospitals Dorset, and the company has a strategic partnership with Stratus to support scalable US deployment. Neuronostics plans to pursue FDA clearance (with a submission planned for 2026) and to extend the platform to provide brain fingerprints of treatment response in pharmaceutical trials. The company highlights clinical needs such as long diagnostic wait times, high misdiagnosis rates, and the high rate of inconclusive routine EEGs as drivers for its adoption.

Participated · Equity · May 2026

Founded in 2024 by Dr Joe Inglis and co-founder Louise Cooke, Luna Pet Healthcare operates dedicated dental-only veterinary clinics and currently has sites in Bristol and Reading. The business aims to make preventative and restorative dental care more affordable and accessible for dogs and cats and has launched a range of at-home preventative dental health products. Luna positions itself as the UK’s first dental-only veterinary operator and focuses on expert-led, proactive veterinary dental care and ongoing pet owner support. The company plans to use its newly raised capital to open additional clinics across the South West, expand service offerings, and invest in development and marketing of its dental healthcare products. The article does not disclose revenue, user, or valuation metrics.

Participated · Seed · Aug 2025

EnsiliTech’s patented Ensilication technology applies tiny inorganic silica layers to individual biological molecules, creating protective cages that keep vaccines, antibodies and other biopharmaceuticals stable outside the cold chain and able to withstand temperatures up to 50°C. The silica coating is biocompatible, inert and inexpensive; when a product is ready for use the cage breaks away leaving the active ingredient intact. The company positions this platform as a way to eliminate expensive, energy-intensive refrigeration in transport and storage, reduce drug waste and broaden access—particularly in regions where reliable cold-chain infrastructure is lacking. EnsiliTech reports early technical efficacy, in vivo safety validation and live commercial negotiations with billion-euro pharma partners, indicating growing commercial momentum. The team is predominantly female-led across leadership and R&D, an attribute that attracted investors focused on female-led businesses. The recent financing will support expansion of capacity, new hires, upgraded infrastructure and critical validation studies to embed Ensilication into pharmaceutical manufacturing processes. EnsiliTech has developed a patented platform technology called ensilication that can be applied to existing and new biopharmaceuticals to make them safe and stable at room temperatures. The technology preserves the integrity of vaccines and other biological materials across a wide temperature range (−20°C to +80°C). The company intends to use recently raised funds to develop a refrigeration-free approach to transporting vaccines and other materials. Ensilication aims to improve vaccine and biological-material distribution in developing countries where reliable refrigeration is a barrier to healthcare. The platform could also enable more rapid and safe distribution of Covid-19 vaccines to communities in need. EnsiliTech is led by Co‑founder and CEO Dr. Asel Sartbaeva and CTO Dr. Aswin Doekhie.

Participated · Equity · May 2024

Intelligent AI has developed a digital platform for insurers and property owners to improve the speed, efficiency, and accuracy of property risk assessments, reducing costs and enabling more appropriate policies. The company is part of the Tech South West Growth Forge accelerator and has secured a multi-million pound UK reseller agreement to take its platform to market. Intelligent AI is headquartered in Exeter and also has an office in Newquay; it was founded in 2020. In May 2024 the company raised £800,000 in new funding. With the latest funding, Intelligent AI plans to double its team and broaden its national footprint. The article does not disclose operating revenue or user metrics. Intelligent AI builds a cloud-based intelligent risk platform that creates digital twins of physical properties to map and quantify risk for insurers. The platform analyzes more than 300 data points, including satellite imagery, to generate accurate property risk data without costly onsite surveys. Its product is aimed at helping insurers write policy terms and predict risk on commercial properties more accurately. The company is part of the Innovate UK–funded KnowRisk Consortium, linking insurance, supply chain and audit risk for a 360-degree enterprise view. Future product development includes a risk report analyzer feature that converts reports into risk mitigation programs. Intelligent AI is led by founder and CEO Anthony Peake and is based in Exeter, UK.